Search research articles
Contact Us
Filters
Showing results (101-110 of 166) with videos related to
Page
of 17
Sort By:
Paediatric Drugs
|
May 5, 2025
Correction: Optimising Paediatric HIV Treatment: Recent Developments and Future Directions
Anne E M Kamphuis, Alasdair Bamford, Alfredo Tagarro, et al.
The Pediatric Infectious Disease Journal
|
May 11, 2010
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand
Nirun Vanprapar, Tim R Cressey, Kulkanya Chokephaibulkit, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 5, 2023
Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight Bands
Suthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 7, 2015
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults
Wasna Sirirungsi, Saik Urien, Linda Harrison, et al.
Clinical Pharmacology and Therapeutics
|
January 22, 2024
Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa
Suthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
The Pediatric Infectious Disease Journal
|
January 8, 2024
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age
Adrie Bekker, Jincheng Yang, Jiajia Wang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 9, 2013
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy
Regis Kreitchmann, Brookie M Best, Jiajia Wang, et al.
The Journal of Antimicrobial Chemotherapy
|
August 2, 2024
Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study
Adrie Bekker, Edmund V Capparelli, Mark Mirochnick, et al.
British Journal of Clinical Pharmacology
|
January 12, 2013
Reduced indinavir exposure during pregnancy
Tim R Cressey, Brookie M Best, Jullapong Achalapong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 11, 2017
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
Tim R Cressey, Baralee Punyawudho, Sophie Le Coeur, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 166) with videos related to
Sort By:
Page
of 17
Paediatric Drugs
|
May 5, 2025
Correction: Optimising Paediatric HIV Treatment: Recent Developments and Future Directions
Anne E M Kamphuis, Alasdair Bamford, Alfredo Tagarro, et al.
The Pediatric Infectious Disease Journal
|
May 11, 2010
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand
Nirun Vanprapar, Tim R Cressey, Kulkanya Chokephaibulkit, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 5, 2023
Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight Bands
Suthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 7, 2015
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults
Wasna Sirirungsi, Saik Urien, Linda Harrison, et al.
Clinical Pharmacology and Therapeutics
|
January 22, 2024
Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa
Suthunya Chupradit, Dalton C Wamalwa, Elizabeth Maleche-Obimbo, et al.
The Pediatric Infectious Disease Journal
|
January 8, 2024
Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age
Adrie Bekker, Jincheng Yang, Jiajia Wang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
February 9, 2013
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy
Regis Kreitchmann, Brookie M Best, Jiajia Wang, et al.
The Journal of Antimicrobial Chemotherapy
|
August 2, 2024
Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study
Adrie Bekker, Edmund V Capparelli, Mark Mirochnick, et al.
British Journal of Clinical Pharmacology
|
January 12, 2013
Reduced indinavir exposure during pregnancy
Tim R Cressey, Brookie M Best, Jullapong Achalapong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
May 11, 2017
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates
Tim R Cressey, Baralee Punyawudho, Sophie Le Coeur, et al.
Page
of 17